Shanghai Longyao Biotechnology Inc., Ltd.
6 clinical trials · Sponsor
◉ Watch Shanghai Longyao Biotechnology Inc., Ltd.
| Record | Firm | Date |
|---|---|---|
| An Evaluation of LY007 Cell Injection for r/r B-NHL (NCT06279611) | Shanghai Longyao Biotechnology Inc., Ltd. | 2021-12-25 |
| A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma (NCT04977193) | Shanghai Longyao Biotechnology Inc., Ltd. | 2021-11-01 |
| Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer (NCT04966143) | Shanghai Longyao Biotechnology Inc., Ltd. | 2021-08-01 |
| The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma (NCT04169932) | Shanghai Longyao Biotechnology Inc., Ltd. | 2019-11-22 |
| The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04166838) | Shanghai Longyao Biotechnology Inc., Ltd. | 2019-11-08 |
| Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma (NCT03207178) | Shanghai Longyao Biotechnology Inc., Ltd. | 2017-03-01 |
Track Shanghai Longyao Biotechnology Inc., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.